Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.48 HKD
Change Today -0.30 / -1.79%
Volume 1.2M
963 On Other Exchanges
Hong Kong
As of 4:01 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

bloomage biotechnology (963) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/3/14 - $22.35
52 Week Low
12/17/14 - $9.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BLOOMAGE BIOTECHNOLOGY (963)

Related News

No related news articles were found.

bloomage biotechnology (963) Related Businessweek News

No Related Businessweek News Found

bloomage biotechnology (963) Details

Bloomage BioTechnology Corporation Limited, an investment holding company, develops, manufactures, and sells bio-chemical products. It produces and sells hyaluronic acid (HA) raw materials used in pharmaceutical, cosmetic, and healthcare products. The company’s HA end products comprise hyaluronan soft tissue filling gel and medical sodium hyaluronate gel for ophthalmologic use, as well as bone products for intra-articular injection. It also develops, distributes, and sells medical devices, as well as sells beauty products. Bloomage BioTechnology Corporation Limited sells its products primarily in the People’s Republic of China, Asia, and the Americas. The company was founded in 2003 and is based in Jinan, the People’s Republic of China.

568 Employees
Last Reported Date: 04/16/15
Founded in 2003

bloomage biotechnology (963) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: CNY3.8M
Executive Director and Member of Nomination C...
Total Annual Compensation: CNY751.0K
Executive Director
Total Annual Compensation: CNY438.0K
Compensation as of Fiscal Year 2014.

bloomage biotechnology (963) Key Developments

Bloomage BioTechnology Corporation Limited Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015

Bloomage BioTechnology Corporation Limited Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015 . Venue: Credit Suisse Office, Level 88, International Commerce Center, 1 Austin Road West, Kowloon, Hong Kong.

Bloomage Biotechnology Corporation Limited Proposes Final Dividend for the Year Ended December 31, 2014

Bloomage BioTechnology Corporation Limited announced that at its AGM to be held on June 18, 2015, proposed final dividend of 2.5 Hong Kong cents per share for the year ended December 31, 2014.

Bloomage BioTechnology Corporation Limited Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014; Proposes Final Dividend, Payable on or Around July 22, 2015

Bloomage BioTechnology Corporation Limited reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported turnover of RMB 481.301 million compared to RMB 375.180 million a year ago. Profit from the operation was RMB 207.738 million compared to RMB 135.742 million a year ago. Profit before taxation was RMB 198.121 million compared to RMB 125.759 million a year ago. Profit for the year was RMB 162.066 million compared to RMB 94.397 million a year ago. Profit attributable to equity shareholders of the Company was RMB 162.067 million compared to RMB 94.398 million a year ago. Diluted earnings per share was RMB 0.473 compared to RMB 0.282 a year ago. Net cash generated from operating activities for the year ended December 31, 2014 was approximately RMB 137.473 million compared to RMB 155.327 million a year ago. The Board of the company proposed the payment of a final dividend of 2.5 cents per share against 1.9 cents per share paid a year ago, to the Shareholders whose names appear on the register of members of the company on June 29, 2015. Subject to the approval of the shareholders at the forthcoming annual general meeting, it is expected that the final dividend will be paid on or around July 22, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
963:HK $16.48 HKD -0.30

963 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 963.
View Industry Companies

Industry Analysis


Industry Average

Valuation 963 Industry Range
Price/Earnings 27.9x
Price/Sales 9.1x
Price/Book 5.8x
Price/Cash Flow 27.2x
TEV/Sales 8.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLOOMAGE BIOTECHNOLOGY, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at